Oil based nanocarrier system for transdermal delivery of ropinirole: A mechanistic, pharmacokinetic and biochemical investigation
Abstract
Ropinirole, a recent introduction in the clinical treatment of Parkinson's disease, suffers with the problems of low oral bioavailability and frequent dosing. An effective transdermal nano-emulsion drug delivery system can however resolve these issues effectively with greater therapeutic benefits and clinical significance. Therefore, the present work focuses precisely on pharmacokinetic, biochemical and mechanistic assessment of transdermal nanoemulsion gel in rats induced with Parkinson lesioned brain by 6-OHDA. DSC and FT-IR studies showed that NEG affects the normal lipid packing of stratum corneum to enhance the drug permeation. Study of pharmacokinetic parameters (AUC, C(max), and T(max)) revealed a greater and more extended release of ropinirole from nanoemulsion gel compared to that from a conventional gel (RPG) and oral marketed tablet (Ropitor). The AUC(0→∞) for RPCNG and RPTNG was found to be 928.07 ± 206.5 and 1055.99 ± 251.7 ngh/mL, respectively in comparison to 137.25 ± 31.3 and 467.15 ± 106.1 ngh/mL for RPG and oral tablet, respectively. The relative bioavailability of ropinirole has been enhanced more than two fold by RPTNG. Furthermore, antiparkinson activity was evaluated in terms of estimating the level of thiobarbituric acid reactive substances, glutathione antioxidant enzymes and catalase in lesioned brain of rats. Formulations were also found to be non-toxic and non-irritant by histological investigations.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nanocarrier-based transdermal delivery of ropirinole restored deviated oxidative stress markers in PD rat model.
“In another study, nanocarrier-based transdermal delivery of the DA agonist ropirinole restored deviated oxidative stress markers such as thiobarbituric acid, glutathione antioxidant enzymes and catalase in the PD rat model.125”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [125]
Cites
Jollow, D. J., Mitchell, J. R., ZAMPAGLIONE, N. G., & Gillette, J. R. (2008) · Pharmacology · doi:10.1159/000136485 · Cited by 3,291 · see citing works
Reactive Oxygen Species and the Central Nervous System
Halliwell, B. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10990.x · Cited by 2,947 · see citing works
CRC handbook of methods for oxygen radical research
Bogomolets, B. B. (1985) · Experimental Gerontology · doi:10.1016/0531-5565(85)90021-x · Cited by 1,554 · see citing works
What contributes to quality of life in patients with Parkinson's disease?
Schrag, A. E. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.3.308 · Cited by 1,380 · see citing works
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050 · see citing works
Infrared spectroscopy of biomolecules
Howland, J. L. (1996) · Biochemical Education · doi:10.1016/0307-4412(96)82531-3 · Cited by 799 · see citing works
Nanoemulsion components screening and selection: A technical note
Azeem, A., Rizwan, M., Ahmad, F. J., Iqbal, Z., Khar, R. K., Aqil, M., & Talegaonkar, S. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-008-9178-x · Cited by 567 · see citing works
Self-citationFloyd, R. A., & Carney, J. M. (1992) · Annals of Neurology · doi:10.1002/ana.410320706 · Cited by 541 · see citing works
Fundamentals of Experimental Pharmacology.
Ghosh, M. N. (1939) · Annals of Internal Medicine · doi:10.7326/0003-4819-12-11-1902_2 · Cited by 519 · see citing works
Levodopa in the treatment of Parkinson's disease: Current controversies
Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonucelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., et al. (2004) · Movement Disorders · doi:10.1002/mds.20243 · Cited by 370 · see citing works
Prostaglandin D2 formation and characterization of its synthetases in various tissues of adult rats
Ujihara, M., Urade, Y., Eguchi, N., Hayashi, H., Ikai, K., & Hayaishi, O. (1988) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(88)90477-8 · Cited by 256 · see citing works
Fundamentals of experimental pharmacology
Chopra, K. (2020) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_1113_20 · Cited by 242 · see citing works
Direct economic impact of Parkinson's disease: A research survey in the United Kingdom
Findley, L. J. J., Aujla, M., Bain, P. G., Baker, M. G., Beech, C., Bowman, C., Holmes, J., Kingdom, W. K., MacMahon, D. G., Peto, V., et al. (2003) · Movement Disorders · doi:10.1002/mds.10507 · Cited by 227 · see citing works
Transdermal drug delivery of imipramine hydrochloride. I. Effect of terpenes
Jain, A. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00524-7 · Cited by 225 · see citing works
Oxy-radical toxicity in catecholamine neurons.
Cohen, G. (1984) · PubMed · Cited by 224 · see citing works
Transdermal delivery of zidovudine: effect of terpenes and their mechanism of action
Narishetty, S. T. K., & Panchagnula, R. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.11.022 · Cited by 206 · see citing works
Suboptimal medication adherence in Parkinson's disease
Grosset, K. A., Bone, I., & Grosset, D. G. (2005) · Movement Disorders · doi:10.1002/mds.20602 · Cited by 206 · see citing works
Clinical Pharmacokinetics of Ropinirole
Kaye, C. M., & Nicholls, B. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039040-00001 · Cited by 177 · see citing works
Vaddi, H. K., Ho, P. C., & Chan, S. Y. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10160 · Cited by 168 · see citing works
The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson??s Disease
Chase, T. N. (1998) · Drugs · doi:10.2165/00003495-199855001-00001 · Cited by 167 · see citing works
Pharmacokinetic Optimisation in the Treatment of Parkinson???s Disease
Nyholm, D. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645020-00001 · Cited by 163 · see citing works
Panchagnula, R., Salve, P. S., Thomas, N. S., Jain, A., & Ramarao, P. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00634-2 · Cited by 138 · see citing works
TKANSPORT INTO AND WITHIN THE SKIN
Blank, I. H., & Scheuplein, R. J. (1969) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1969.tb16056.x · Cited by 112 · see citing works
Spherical lipid bilayer membranes: Electrical and isotopic studies of ion permeability
Pagano, R. E., & Thompson, T. E. (1968) · Journal of Molecular Biology · doi:10.1016/0022-2836(68)90127-7 · Cited by 82 · see citing works
Formulation of microemulsion systems for transdermal delivery of aceclofenac
Lee, J., Lee, Y., Kim, J., Yoon, M.-K., & Choi, Y. W. (2005) · Archives of Pharmacal Research · doi:10.1007/bf02977408 · Cited by 79 · see citing works
Mechanisms of Transdermal Drug Delivery
Walters, K. A. (1998) · The Journal of the British Menopause Society · doi:10.1177/136218079800400205 · Cited by 75 · see citing works
Akhter, S., Jain, G. K., Ahmad, F. J., Khar, R. K., Jain, N., Khan, Z. I., & Talegaonkar, S. (2008) · Current Nanoscience · doi:10.2174/157341308786306071 · Cited by 73 · see citing works
Self-citationOxidative Stress to Dopaminergic Neurons as Models of Parkinson's Disease
GILLE, G., HUNG, S., REICHMANN, H., & RAUSCH, W. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1296.066 · Cited by 53 · see citing works
Skin permeation mechanism of aceclofenac using novel nanoemulsion formulation
Shakeel, F., Baboota, S., Ahuja, A., All, J. D., & Shafiq, S. (2008) · Die Pharmazie · doi:10.31083/ph.2008.8036 · Cited by 46 · see citing works
Enhancement of transdermal penetration of dapiprazole through hairless mouse skin
Monti, D., Saettone, M. F., Giannaccini, B., & Galli-Angeli, D. (1995) · Journal of Controlled Release · doi:10.1016/0168-3659(94)00079-a · Cited by 43 · see citing works
Components Screening and Influence of Surfactant and Cosurfactant on Nanoemulsion Formation
Azeem, A., Rizwan, M., Ahmad, F. J., Khar, R. K., Iqbal, Z., & Talegaonkar, S. (2009) · Current Nanoscience · doi:10.2174/157341309788185505 · Cited by 41 · see citing works
Self-citationEnhanced transdermal delivery of carvedilol using nanoemulsion as a vehicle
Rizwan, M., Aqil, M., Azeem, A., Talegaonkar, S., Sultana, Y., & Ali, A. (2010) · Journal of Experimental Nanoscience · doi:10.1080/17458080903583964 · Cited by 27 · see citing works
Self-citationZafar, K. S., Siddiqui, A., Sayeed, I., Ahmad, M., Saleem, S., & Islam, F. (2003) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2003.08.001 · Cited by 27 · see citing works
In vivo iontophoretic administration of ropinirole hydrochloride
Álvarez, A. L., Delgado-Charro, M. B., & Blanco-Méndez, J. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10502 · Cited by 22 · see citing works
Reply: Levodopa in the treatment of Parkinson's disease: Current controversies
Olanow, C. W., Agid, Y., & Mizuno, Y. (2005) · Movement Disorders · doi:10.1002/mds.20426 · Cited by 5 · see citing works
Flagged first, then by citations
1 of the 36 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Çetinel, S., Zuvin, M., Koşar, A., & Kutlu, Ö. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,103 · see citing works
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645 · see citing works
Rai, V. K., Mishra, N., Yadav, K. S., & Yadav, N. P. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.049 · Cited by 623 · see citing works
Recent advances in gel technologies for topical and transdermal drug delivery
Rehman, K. S., & Zulfakar, M. H. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2013.828219 · Cited by 266 · see citing works
Critical evaluation of biodegradable polymers used in nanodrugs
Caballero‐George, C., Marin, & Briceño (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s47186 · Cited by 256 · see citing works
Khurana, S., Jain, S., & Bedi, P. M. S. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.005 · Cited by 224 · see citing works
Nanoemulsions: increasing possibilities in drug delivery
Sutradhar, K. B., & Amin, M. L. (2013) · European Journal of Nanomedicine · doi:10.1515/ejnm-2013-0001 · Cited by 216 · see citing works
Shakeel, F., Shafiq, S., Haq, N., Alanazi, F. K., & Alsarra, I. A. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.696605 · Cited by 136 · see citing works
Ray, S., Sinha, P., Laha, B., Maiti, S., Bhattacharyya, U. K., & Nayak, A. K. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.08.016 · Cited by 122 · see citing works
Dudhipala, N. R., & Gorre, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050448 · Cited by 121 · see citing works
Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases
Gendelman, H. E., Anantharam, V., Bronich, T. K., Ghaisas, S., Jin, H., Kanthasamy, A. G., Liu, X., McMillan, J., Mosley, R. L., Narasimhan, B., et al. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.12.014 · Cited by 117 · see citing works
Raviadaran, R., Chandran, D., Shin, L. H., & Manickam, S. (2018) · LWT · doi:10.1016/j.lwt.2018.05.022 · Cited by 113 · see citing works
Pehlivan, S. B. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1156-7 · Cited by 113 · see citing works
Aggarwal, N., Goindi, S., & Khurana, R. (2013) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2013.01.004 · Cited by 108 · see citing works
Nanoparticles: A Hope for the Treatment of Inflammation in CNS
Zhu, F.-D., Hu, Y.-J., Yu, L., Zhou, X.-G., Wu, J.-M., Tang, Y., Qin, D.-L., Fan, Q., & Wu, A.-G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683935 · Cited by 87 · see citing works
Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's
Nirale, P., Paul, A., & Yadav, K. S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117394 · Cited by 103 · see citing works
Nanoemulsions in CNS drug delivery: recent developments, impacts and challenges
Karami, Z., Zanjani, M. R. S., & Hamidi, M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.021 · Cited by 99 · see citing works
Pardeshi, C. V., Belgamwar, V. S., Tekade, A. R., & Surana, S. J. (2013) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-013-4965-7 · Cited by 95 · see citing works
Kaur, G., Panigrahi, C., Agarwal, S., Khuntia, A., & Sahoo, M. (2024) · Food Physics · doi:10.1016/j.foodp.2024.100024 · Cited by 89 · see citing works
Zhao, L., Wang, Y., Zhai, Y., Wang, Z., Liu, J., & Zhai, G. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.10.005 · Cited by 87 · see citing works
Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems
Garbayo, E., Ansorena, E., & Blanco‐Prieto, M. J. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.05.019 · Cited by 83 · see citing works
Roy, A., Nishchaya, K., & Rai, V. K. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2045944 · Cited by 67 · see citing works
Nanomaterial applications for neurological diseases and central nervous system injury
Huang, L., Hu, J., Huang, S., Wang, B. Z., Siaw-Debrah, F., Nyanzu, M. K., Zhang, Y., & Zhuge, Q. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.07.003 · Cited by 65 · see citing works
Elnaggar, Y. S. R., Talaat, S. M., Bahey-El-Din, M., & Abdallah, O. Y. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117817 · Cited by 63 · see citing works
Kumar, N., & Shishu (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.10.014 · Cited by 62 · see citing works
abood, R. M. A., Talegaonkar, S., Tariq, M., & Ahmad, F. J. (2012) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2012.06.015 · Cited by 62 · see citing works
Self-citationNanobiomaterials’ applications in neurodegenerative diseases
Silva‐Adaya, D., Aguirre‐Cruz, L., Guevara, J., & Ortiz-Islas, E. (2016) · Journal of Biomaterials Applications · doi:10.1177/0885328216659032 · Cited by 61 · see citing works
Yi, Q., Jin, Y., Tang, S., Huang, H., & Kang, L. (2015) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2015.1107095 · Cited by 60 · see citing works
Nanocarriers enhance the transdermal bioavailability of resveratrol: In-vitro and in-vivo study
Tsai, M., Lu, I.-J., Fu, Y., Fang, Y., Huang, Y., & Wu, P. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.09.045 · Cited by 57 · see citing works
Crasta, A., PAINGINKAR, T., Sreedevi, A., Pawar, S. D., Sathyanarayana, M. B., Vasantharaju, S. G., Osmani, R. A. M., & Ravi, G. (2025) · OpenNano · doi:10.1016/j.onano.2025.100245 · Cited by 54 · see citing works
Chaturvedi, S., & Garg, A. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102355 · Cited by 53 · see citing works
Wang, Y., Yu, X., Zhang, P., Ma, Y., Wang, L., Xu, H., & Sui, D. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.08.008 · Cited by 52 · see citing works
Lin, Y.-H., Tsai, M., Fang, Y., Fu, Y., Huang, Y., & Wu, P. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.10.015 · Cited by 51 · see citing works
Sita, V. G., & Vavia, P. R. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-1620-8 · Cited by 49 · see citing works
Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders
Guo, Z.-H., Khattak, S., Rauf, M. A., Ansari, M. A., Alomary, M. N., Razak, S., Yang, C., Wu, D., & Ji, X. (2023) · Molecules · doi:10.3390/molecules28031283 · Cited by 49 · see citing works
Continuous Drug Delivery in Parkinson’s Disease
Senek, M., & Nyholm, D. (2013) · CNS Drugs · doi:10.1007/s40263-013-0127-1 · Cited by 48 · see citing works
Advances in Nanomedicine for the Treatment of Alzheimer’s and Parkinson’s Diseases
Hernando, S., Gartziandia, O., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0019 · Cited by 48 · see citing works
Nehal, N., Nabi, B., Rehman, S., Pathak, A., Iqubal, A., Khan, S. A., Yar, M. S., Parvez, S., Baboota, S., & Ali, J. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.207 · Cited by 48 · see citing works
Yadav, V. K., Dhanasekaran, S., Choudhary, N., Nathiya, D., Thakur, V., Gupta, R., Pramanik, S., Kumar, P., Gupta, N., & Patel, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1535682 · Cited by 50 · see citing works
Caro, V. D., Giandalia, G., Siragusa, M. G., Sutera, F. M., & Giannola, L. I. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.022 · Cited by 46 · see citing works
Hung, W.-H., Chen, P.-K., Fang, C.-W., Lin, Y., & Wu, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030410 · Cited by 40 · see citing works
Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs
Silva, S., Almeida, A. J., & Vale, N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040508 · Cited by 40 · see citing works
Patel, P. A., Pol, A. S., Kalaria, D. R., Date, A. A., Kalia, Y. N., & Patravale, V. B. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.04.026 · Cited by 33 · see citing works
Kumar, N., & Goindi, S. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.06.030 · Cited by 33 · see citing works
Aggarwal, N., & Goindi, S. (2013) · Journal of Nanoparticle Research · doi:10.1007/s11051-013-1983-9 · Cited by 32 · see citing works
Fuster, J., Negro, S., Salama, A., Fernández-Carballido, A. M., Marcianes, P., Boeva, L., & Barcia, E. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.06.035 · Cited by 32 · see citing works
Setya, S., Madaan, T., Tariq, M., Razdan, B., & Talegaonkar, S. (2017) · AAPS PharmSciTech · doi:10.1208/s12249-017-0868-0 · Cited by 31 · see citing works
Self-citationYang, M., Gu, Y., Tang, X., Wang, T., & Liu, J. (2019) · Current Drug Delivery · doi:10.2174/1567201816666190118125427 · Cited by 30 · see citing works
Potential applications of nanomedicine for treating Parkinson's disease
Shankar, J., Geetha, K. M., & Wilson, B. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102793 · Cited by 28 · see citing works
Nanomedicine to Overcome Current Parkinson’s Treatment Liabilities: A Systematic Review
Hawthorne, G. H., Bernuci, M. P., Bortolanza, M., Tumas, V., Issy, A. C., & Bel, E. A. D. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9663-z · Cited by 24 · see citing works
Sharma, A., Muresanu, D. F., Nozari, A., Lafuente, J. V., Sahib, S., Tian, Z. R., Buzoianu, A. D., Patnaik, R., Wiklund, L., & Sharma, H. S. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.09.010 · Cited by 23 · see citing works
Vu, Q. L., Fang, C.-W., Suhail, M., & Wu, P. (2021) · Pharmaceuticals · doi:10.3390/ph14121233 · Cited by 23 · see citing works
Tremblay, M., Barrus, M., Cocker, P., Baunez, C., & Winstanley, C. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5173-z · Cited by 18 · see citing works
Nanobiotechnology in Neurodegenerative Diseases
Jampílek, J., Kráľová, K., Novák, P., & Novák, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_4 · Cited by 22 · see citing works
Talaat, S. M., Elnaggar, Y. S. R., & Abdalla, O. Y. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1374-3 · Cited by 19 · see citing works
Setya, S., Madaan, T., Razdan, B., Farswan, M., & Talegaonkar, S. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191022105036 · Cited by 19 · see citing works
Self-citationNanoparticles for transdermal drug delivery system (TDDS)
Tomoda, K., & Makino, K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-444-62614-1.00007-7 · Cited by 18 · see citing works
El-Leithy, E. S., Makky, A. M. A., Khattab, A., & Hussein, D. G. (2017) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2017v9i11.21751 · Cited by 18 · see citing works
Advances and challenges in nintedanib drug delivery
Velagacherla, V., Suresh, A., Mehta, C. H., & Nayak, U. Y. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1985460 · Cited by 16 · see citing works
Casanova, Y., Negro, S., & Barcia, E. (2021) · Acta Pharmaceutica · doi:10.2478/acph-2022-0008 · Cited by 17 · see citing works
Ahmad, N., Amin, S., Neupane, Y. R., & Kohli, K. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.876004 · Cited by 14 · see citing works
Nanodelivery of therapeutic agents in Parkinson's disease
Lafuente, J. V., Requejo, C., & Ugedo, L. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.004 · Cited by 14 · see citing works
Sharma, N., Ojha, H., Pathak, D. P., Goel, R., & Sharma, R. K. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.11.007 · Cited by 13 · see citing works
"Nanomedicine and Nano Formulations for Neurodegenerative Diseases"
Pathak, Y. V. (2022) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2022.42.006713 · Cited by 11 · see citing works
Lu, I.-J., Fu, Y., Chang, W., & Wu, P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190527091528 · Cited by 10 · see citing works
Khan, S. A., & Haider, M. F. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273323074241001071645 · Cited by 7 · see citing works
Potential advancements of nanocarriers in topical drug delivery: a mini review
(2020) · Letters in Applied NanoBioScience · doi:10.33263/lianbs92.968974 · Cited by 7 · see citing works
De, S., Banerjee, S., Rakshit, P., Banerjee, S., & Kumar, S. K. A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998291968240429111357 · Cited by 6 · see citing works
Sadashivaiah, R., & Babu, B. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2020.1791167 · Cited by 6 · see citing works
Advances in hydrogel for diagnosis and treatment for Parkinson’s disease
Zhu, P., Zhao, Z., & Gao, Y.-F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1552586 · Cited by 5 · see citing works
Nanotechnology and Parkinson’s disease
Mavridis, I. N., Meliou, M., Pyrgelis, E.-S., & Agapiou, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813667-6.00001-2 · Cited by 5 · see citing works
Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease
De, S., & Kuo, Y. (2024) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2024.105401 · Cited by 5 · see citing works
Mantry, S., & Balaji, A. (2017) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i7.18475 · Cited by 5 · see citing works
Recent advancements in lipid-based nanocarriers for transdermal drug delivery
Parhi, R., Mohanta, B. C., Jena, G. K., & Sahoo, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95171-5.00001-7 · Cited by 4 · see citing works
Yan, X., Zhao, S., Zhu, W., Rao, J., Li, K., Xu, J., Li, D., Qin, L., Qiu, L., Gao, L., et al. (2016) · Bioanalysis · doi:10.4155/bio-2016-0087 · Cited by 4 · see citing works
Drug delivery and functional nanoparticles
Roy, D., Modi, A., Ghosh, R., & Benito‐León, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91783-4.00018-8 · Cited by 4 · see citing works
Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment
Hernando, S., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-57696-1_3 · Cited by 4 · see citing works
Nanoparticles for Drug Delivery in Parkinson's Disease: A Review of Potential Applications
Bagheri, A. M., & Ranjbar, M. (2024) · The Neuroscience Journal of Shefaye Khatam · doi:10.61186/shefa.12.4.67 · Cited by 3 · see citing works
Nanotherapeutics a promising approach for treatment of Parkinson’s disease
Bhalothia, C., & Nagda, G. (2022) · Materials Today Proceedings · doi:10.1016/j.matpr.2022.10.311 · Cited by 3 · see citing works
Nanodiagnostics and targeted drug delivery: integrated technologies
Trivedi, S., Kamdar, A., Bhoyar, V. T., & Belgamwar, V. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91763-6.00011-4 · Cited by 3 · see citing works
Ali, S. K., & Al-Akkam, E. J. (2024) · Journal of the Faculty of Medicine Baghdad · doi:10.32007/jfacmedbagdad.6622210 · Cited by 2 · see citing works
Advances in Nanotechnology for Drug Delivery Modulation in Neurodegenerative Diseases
Abdel-Dayem, D., Emara, H. M., Elshafey, B., & Salama, M. M. (2024) · Springer eBooks · doi:10.1007/978-981-99-7557-0_9 · Cited by 2 · see citing works
Arakha, M., & Jha, S. (2018) · Series in bioengineering · doi:10.1007/978-3-319-73326-5_1 · Cited by 2 · see citing works
Nanomaterial-based drug delivery systems as tools for targeted therapy of neurodegenerative diseases
Shukla, R., Srivastava, V., Sethi, A., & Ruwali, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00003-4 · Cited by 2 · see citing works
Clinical potential of nanotechnlogy as smart therapeutics: A step toward targeted drug delivery
Saha, P., Bose, S., Javed, M. N., & Srivastava, A. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88450-1.00024-7 · Cited by 1 · see citing works
Siddique, N. (2023) · Pharmaceutical Sciences and Research · doi:10.7454/psr.v10i2.1265 · Cited by 1 · see citing works
Antonara, L., Rekkas, D. M., Pippa, Ν., & Dallas, P. P. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121571 · Cited by 1 · see citing works
Fang, C.-W., Lin, Y.-W., Chiu, I.-H., & Wu, P. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100469 · Cited by 1 · see citing works
Saxena, R., & Lohani, A. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100466 · Cited by 1 · see citing works
de Moraes, J. P., Signori, L. U., Rambo, B. V. C., Mussoi, T. D., Laporta, L. V., Franco, C., & Rech, V. C. (2022) · Disciplinarum Scientia | Naturais e Tecnológicas · doi:10.37779/nt.v22i3.4108 · Cited by 1 · see citing works
Crossing the SC: Targeting and mechanism of andrographolide via nano-emulsion system
Wu, M., Wang, J., Chen, Q., & Ding, Z. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.116
Improvement of anti-inflammation of swietenia macrophylla self nanoemulsion
Eid, A. M., & Mustafa, A. (2015)
Zuvin, M. (2019) · Sabanci University
Lipid Nanoemulsion Regulates Parkinson’s Cell Cycle and Proliferation Through miR-199/NF-κB Pathway
Liu, J., Yu, F., Wang, P., Yang, J., Geng, S., Zhao, S., & Wang, B. (2022) · Science of Advanced Materials · doi:10.1166/sam.2022.4253
Advances in Nanotechnology for Drug Delivery Modulation in Neurodegenerative Diseases
Abdel-Dayem, D., Emara, H. M., Elshafey, B., & Salama, M. (2023) · Springer eBooks · doi:10.1007/978-981-19-3949-5_9-1
HOPES AND HURDLES OF DENDRIMERS FOR THE TREATMENT OF PARKINSON’S DISEASE
AGGARWAL, K., Verma, S., RATHORE, A. S., & Parashar, T. (2025) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2025v18i6.54401
Frangieh, M. R., Saad, M., Fattouh, N., & Sawan, S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119903
Zhang, F., Ju, X., He, M., Sun, S., Kong, S., & Luo, H. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104512
- Authors
- Azeem, A., Talegaonkar, S., Negi, L. M., Ahmad, F. J., Khar, R. K., & Iqbal, Z.
- Affiliations
- Jubilant Life Sciences (India) (IN)
- Jamia Hamdard (IN)
- Corresponding author
- Talegaonkar, Sushama
- Venue
- International Journal of Pharmaceutics
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 422
- Issue
- 1-2
- Pages
- 436-444
- ISSN
- 0378-5173 (ISSN-L)
- OpenAlex
- W2026763513
- Cited by
- 99
- References
- 36
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 9 · 2020: 9 · 2019: 10 · 2018: 5 · 2017: 7 · 2016: 7 · 2015: 4 · 2014: 5 · 2013: 11 · 2012: 3
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- ropinirole, transdermal drug delivery, nanoemulsion gel, Parkinson's disease, skin permeation, pharmacokinetics, relative bioavailability, antioxidant enzymes, catalase, glutathione, TBARS
- MeSH terms
- Administration, Cutaneous, Administration, Oral, Animals, Antiparkinson Agents, Biological Availability, Brain, Calorimetry, Differential Scanning, Catalase, Chemistry, Pharmaceutical, Delayed-Action Preparations, Disease Models, Animal, Dihydroxyphenylalanine, Drug Carriers, Drug Compounding, Emulsions, Gels, Glutathione, Indoles, Male, Oils, Skin Absorption, Tablets, Technology, Pharmaceutical, Rats, Wistar, Thiobarbituric Acid Reactive Substances, Spectroscopy, Fourier Transform Infrared, Parkinsonian Disorders, Nanotechnology, Rats, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
